<DOC>
	<DOCNO>NCT01757145</DOCNO>
	<brief_summary>The purpose study determine whether Eltrombopag may shorten time platelet engraftment allogeneic cord blood transplantation .</brief_summary>
	<brief_title>Eltrombopag Enhancing Platelet Engraftment Adult Patients Undergoing Cord Blood Transplantation</brief_title>
	<detailed_description>Platelet recovery significantly hamper follow umbilical cord blood ( UCB ) transplantation . Median time platelet engraftment ( define first 7 consecutive day unsupported platelet count least 20,000/microliter ) large retrospective study 70 day cumulative incidence platelet recovery 6 month 50.5 % . In pediatric population acute leukemia median time platelet engraftment UCB transplantation 59 day cumulative incidence platelet recovery 6 month 43 % -73 % , depend human leukocyte antigen ( HLA ) disparity cell dose . Recently , cohort adult patient give myeloablative conditioning follow double UCB transplantation , cumulative incidence platelet recovery ( ≥ 50,000/microliter ) 100 day 53 % . In another cohort patient give reduced intensity condition regimen follow single double UCB transplantation , median time platelet recovery ( ≥ 50,000/microliter ) cumulative incidence platelet recovery 6 month 49 day 65 % , respectively . Thus , UCB transplantation , patient platelet transfusion-dependent prolong period time , result many drawback , exposure blood transfusion hazard , high incidence platelet allo-reactivity extend period bleed diathesis undesirable costly long hospitalization . Eltrombopag thrombopoietin-receptor agonist initiate thrombopoietin-receptor signal thereby induce proliferation maturation megakaryocytes.Administration eltrombopag increase platelet production volunteer normal platelet count , patient thrombocytopenia secondary hepatitis C virus infection patient chronic immune thrombocytopenic purpura . We evaluate safety efficacy eltrombopag treatment give early UCB transplantation . The study open non-comparative study . The primary outcome cumulative incidence partial platelet engraftment ( first 7 consecutive day unsupported platelet count least 20,000/microliter ) day 50 post transplantation . Secondary objective safety , tolerability transplantation relate outcome .</detailed_description>
	<mesh_term>Pancytopenia</mesh_term>
	<mesh_term>Hemoglobinuria , Paroxysmal</mesh_term>
	<criteria>1 . Patient ≥ 18 year old . 2 . Patients receive unmanipulated single double umbilical cord blood allogeneic graft . 3 . Malignant non malignant indication transplantation . 4 . Myeloablative reduce intensity conditioning regimen . 5 . Patients must meet pretransplantation criterion transplantation center include acceptable test heart , liver , kidney , lung function ( standard screen transplantation per PI , coinvestigators ) . 6 . Able give write informed consent clinical trial . 7 . Able comply study protocol . 1 . Indications transplantation 1 . Patients primary myelofibrosis . 2 . M7 ( FrenchAmericanBritish classification ) acute myeloid leukemia . Acute leukemia secondary myeloproliferative neoplasm . 3 . Patients persistent acute leukemia ( &gt; 5 % bone marrow blast ) time transplantation . 2 . Patients prior thromboembolic event . Patients previous catheter relate thrombosis eligible 3 month elapse . 3 . Hypersensitivity eltrombopag . 4 . Liver enzymes abnormality : Alanine transaminase ( ALT ) level &gt; 3 time upper limit normal ( ULN ) serum bilirubin &gt; 1.5 ULN ( unless due Gilbert 's syndrome hemolytic bilirubin ) . 5 . Pregnancy : Women childbearing potential men must agree use contraception prior study entry duration study participation . A woman childbearing potential define woman naturally postmenopausal least 12 consecutive month previous surgical sterilization .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Cord blood transplantation</keyword>
	<keyword>Eltrombopag</keyword>
	<keyword>Platelet engraftment</keyword>
</DOC>